Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Guía de práctica clínica sobre el manejo del paciente con dispepsia
Información de la revista
Vol. 26. Núm. 9.
Páginas 571-613 (Enero 2003)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 26. Núm. 9.
Páginas 571-613 (Enero 2003)
DOI: 10.1016/S0210-5705(03)70414-2
Acceso a texto completo
Guía de práctica clínica sobre el manejo del paciente con dispepsia
Visitas
...
JJ. Mascorta, M. Marzob, P. Alonso-Coellob, M. Barenysc, F. Carballoc, M. Fernándezb, LJ. Ferrándiza, X. Bonfillb, JM. Piquéc
a Sociedad Española de Medicina de Familia y Comunitaria
b Centro Cochrane Iberoamericano
c Asociación Española de Gastroenterología
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
N.J. Talley, V. Stanghellini, R.C. Heading, K.L. Koch, J.R. Malagelada, G.N. Tytgat.
Functional gastroduodenal disorders.
Gut, 45 (1999), pp. 37-42
[2.]
Institute for Clinical Systems Improvement.
Health Care Guideline.
[3.]
Aymerich M, Baena JM, Boix C, Carrillo R, Madrilejos R, Mascort JJ et al. Direcció clínica en l'atenció primària. Dispepsia - H. pylori. Guies de pràctica clínica i material docent. http://www.gencat.net/ics/professionals/guies/dispepsia/dispepsia.htm
[4.]
L. Agreus.
Natural history of dyspepsia.
Gut, 50 (2002), pp. 2-9
[5.]
Grupo de trabajo de la guía de práctica clínica sobre ERGE. Manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE). Guía de práctica clínica. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2001 Programa de Elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 1. http://www.guiasgastro.net
[6.]
S.J.O. Veldhuyzen van Zanten, N. Flook, N. Chiba, D. Armstrong, A. Barkun, a.l. Bradette M et.
for the Canadian Dyspepsia Working Group.
An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. CMAJ, 162 (2000), pp. 3-23
[7.]
J.E. Kellow.
Organic causes of dyspepsia, and discriminating functional from organic dyspepsia.
Best Pract Res Clin Gastroenterol, 15 (2001), pp. 477-487
[8.]
R.C. Heading.
Prevalence of upper gastrointestinal symptoms in the general population: a systematic review.
Scand J Gastroenterol Suppl, 231 (1999), pp. 3-8
[9.]
SBU -The Swedish Council on Technology Assessment in Health Care.
Stomach pain -evidence-based methods in the diagnosis and treatment of dyspepsia.
Stockholm, (2000),
[10.]
V. Stanghellini.
Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).
Scand J Gastroenterol Suppl, 231 (1999), pp. 20-28
[11.]
A.M. Caballero Plasencia, S. Sofos Kontoyannis, J.L. Martín Ruiz, M. Valenzuela Barranco.
La prevalencia de la dispepsia en España.
Med Clin (Barc), 103 (1994), pp. 717
[12.]
M.D. Schwartz.
Dyspepsia, peptic ulcer disease, and esophageal reflux disease.
West J Med, 176 (2002), pp. 98-103
[13.]
J.L. Turabian, V. Gutiérrez.
Variaciones en la frecuencia de las enfermedades crónicas y los factores de riesgo en atención primaria: 1985-1995.
Aten Primaria, 18 (1996), pp. 65-69
[14.]
N.J. Talley.
Dyspepsia: management guidelines for the millennium.
Gut, 50 (2002), pp. 72-78
[15.]
O.V. Bazaldua, F.D. Schneider.
Evaluation and management of dyspepsia.
Am Fam Physician, 60 (1999), pp. 1.773-1.788
[16.]
A. Haycox, T. Einarson, A. Eggleston.
The health economic impact of upper gastrointestinal symptoms in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).
Scand J Gastroenterol Suppl, 231 (1999), pp. 38-47
[17.]
N.J. Talley, M.D. Silverstein, L. Agreus, O. Nyren, A. Sonnenberg, G. Holtmann.
AGA technical review: evaluation of dyspepsia. American Gastroenterological Association.
Gastroenterology, 114 (1998), pp. 582-595
[18.]
R.S. Fisher, H.P. Parkman.
Management of non ulcer dyspepsia.
N Engl J Med, 339 (1998), pp. 1.376-1.381
[19.]
M. Barenys, A. Abad, J.M. Pons, V. Moreno, R. Rota, A. Granados, et al.
Scoring system has better discriminative value than Helicobacter pylori testing in patients with dyspepsia in a setting with high prevalence of infection.
Eur J Gastroenterol Hepatol, 12 (2000), pp. 1.275-1.282
[20.]
Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, Version 1.0.IARC Cancer Base n.° 5. Lyon, IARC Press, 2001. Limited version available from: http://www-dep.iarc.fr/globocan/globocan.htm. Last updated on 03/02/2001
[21.]
P. Moayyedi, J. Mason.
Clinical and economic consequences of dyspepsia in the community.
Gut, 50 (2002), pp. 10-12
[22.]
M. Ruiz, F. Vilasante, F. León, V. González-Lara, C. González, M. Crespo, et al.
Cuestionario sobre calidad de vida asociada a dispepsia. Adaptación española y validación del cuestionario Dyspepsia Related Health Scale.
Med Clin (Barc), 117 (2001), pp. 567-573
[23.]
P. Enck, D. Dubois, P. Marquis.
Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).
Scand J Gastroenterol Suppl, 231 (1999), pp. 48-54
[24.]
K.W. Olden.
Are psychosocial factors of aetiological importance in functional dyspepsia?.
Baillieres Clin Gastroenterol, 12 (1998), pp. 557-571
[25.]
K.W. Olden, D.A. Drossman.
Psychologic and psychiatric aspects of gastrointestinal disease.
Med Clin North Am, 84 (2000), pp. 1.313-1.327
[26.]
L. Kay, T. Jorgensen.
Epidemiology of upper dyspepsia in random population. Prevalence, incidence, natural history and risk factors.
Scan J Gastroenterol, 29 (1994), pp. 1-7
[27.]
L.I. Yuyuan, N.I.E. Yuqiang, S.H.A. Weihong, S.U. Hua.
The link between social psychosocial and functional dyspepsia: An epidemiological study.
Chin Med J, 115 (2002), pp. 1.082-1.084
[28.]
V. Stanghellini.
Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).
Scand J Gastroenterol Suppl, 231 (1999), pp. 29-37
[29.]
D. Pantoflickova, A.L. Blum, H.R. Koelz.
Helicobacter pylori and functional dyspepsia: a real causal link?.
Bailleres Clin Gastroenterol, 12 (1998), pp. 503-532
[30.]
J. Danesh, M. Lawrence, M. Murphy, S. Roberts, R. Collins.
Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia.
Arch Intern Med, 160 (2000), pp. 1.192-1.198
[31.]
F. Bazzoli, L. De Luca, P. Pozzato, R.M. Zagari, S. Fossi, L. Ricciardiello, et al.
Helicobacter pylori and functional dyspepsia: review of previous studies and commentary on new data.
Gut, 50 (2002), pp. 33-35
[32.]
G.H. Elta, E.M. Behler, T.J. Colturi.
Comparison of coffee intake and coffee-induced symptoms in patients with duodenal ulcer, nonulcer dyspepsia, and normal controls.
Am J Gastroenterol, 85 (1990), pp. 1.339-1.342
[33.]
S. Nandurkar, N.J. Talley, H. Xia, H. Mitchell, S. Hazel, M. Jones.
Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection.
Arch Intern Med, 158 (1998), pp. 1.427-1.433
[34.]
M. Woodward, C.E. Morrison, K.e. McColl.
The prevalence of dyspepsia and use of antisecretory medicatioin in North Gasgow: role of Helicobacter pylori vs lifestyle factors.
Aliment Pharmacol, 13 (1999), pp. 1.505-1.509
[35.]
P. Bytzer, S. Howell, M. Leemon, L.J. Young, M.P. Jones, N.J. Talley.
Low socioeconomic class is a risk factor for upper and lower gastrointestinal symptoms: a population based study in 15000 Australian adults.
Gut, 49 (2001), pp. 66-67
[36.]
N.J. Talley, A.L. Weaver, A.R. Zinsmeister.
Smoking, alcohol, and nonsteroidal anti-inflammatory drugs in outpatients with functional dyspepsia and among dyspepsia subgroups.
Am J Gastroenterol, 89 (1994), pp. 524-528
[37.]
N.J. Talley, McNeilD, D.W. Piper.
Environmental factors and chronic unexplained dyspepsia. Association with acetaminophen but not other analgesics, alcohol, coffee, tea, or smoking.
Dig Dis Sci, 33 (1988), pp. 641-648
[38.]
J.H. Kurata, A.N. Nogawa.
Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking.
J Clin Gastroenterol, 24 (1997), pp. 2-17
[39.]
J.Q. Huang, S. Sridhar, R.H. Hunt.
Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.
[40.]
F.K. Chan, K.F. To, J.C. Wu, M.Y. Yung, W.K. Leung, T. Kwok, et al.
Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal antiinflammatory drugs: a randomised trial.
Lancet, 359 (2002), pp. 9-13
[41.]
W.L. Straus, J.J. Ofman, C. MacLean, S. Morton, M.L. Berger, E.A. Roth, et al.
Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions.
Am J Gastroentrol, 97 (2002), pp. 1.951-1.958
[42.]
C. Aalykke, K. Lauritsen.
Epidemiology of NSAID-related gastroduodenal mucosal injury.
Best Pract Res Clin Gastroenterol, 15 (2001), pp. 705-722
[43.]
The National Prescribing Center.
Managing dyspepsia: the role of Helicobacter pylori.
MeReC Bulletin, 12 (2001), pp. 1-4
[44.]
P. Moayyedi, A.T. Axon, R. Feltbower, S. Duffett, W. Crocombe, D. Braunholtz, et al.
Relation of adult lifestiles and socioeconomic factors to the prevalence of Helicobacter pylori infection.
Int J Epidemiol, 31 (2002), pp. 624-631
[45.]
R.D. Goodwin, B.S. Murray.
Generalized Anxiety disorder and peptic ulcer disease among adults in the United States.
Psychosomatic Medicine, 64 (2002), pp. 862-866
[46.]
I.B. Andersen, T. Jorgensen, O. Bonnevie, M. Gronbaek, T.I. Sorensen.
Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population-based cohort study.
Epidemiology, 11 (2000), pp. 434-439
[47.]
International Agency for Research on Cancer.
Infection with Helicobacter pylori.
IARC Monogr Eval Carcinog Risks Hum, 61 (1994), pp. 177-240
[48.]
P. Correa.
Gastric neoplasia.
Curr Gastroenterol Rep, 4 (2002), pp. 463-470
[49.]
W.M. Priebe, L.R. DaCosta, I.T. Beck.
Is epigastric tenderness a sign of peptic ulcer disease?.
Gastroenterology, 82 (1982), pp. 16-19
[50.]
M.E. Numans, Y. Van der Graaf, N.J. de Wit, F. Touw-Otten, R.A. de Melker.
How much ulcer is ulcer-like? Diagnostic determinants of peptic ulcer in open access gastroscopy.
Fam Pract, 11 (1994), pp. 382-388
[51.]
T. Johannessen, H. Petersen, P.M. Kleveland, J.H. Dybdahl, A.K. Sandvik, E. Brenna, et al.
The predictive value of history in dyspepsia.
Scand J Gastroenterol, 25 (1990), pp. 689-697
[52.]
J.W. Muris, R. Starmans, P. Pop, H.F. Crebolder, J.A. Knottnerus.
Discriminant value of symptoms in patients with dyspepsia.
J Fam Pract, 38 (1994), pp. 139-143
[53.]
P. Bytzer, J.M. Hansen, T. Havelund, A. Malchow-Moller, O.B. Schaffalitzky de Muckadell.
Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement.
Eur J Gastroenterol Hepatol, 8 (1996), pp. 359-363
[54.]
J.M. Hansen, P. Bytzer, O.B. Schaffalitzky De Muckadell.
Management of dyspeptic patients in primary care. Value of the unaided clinical diagnosis and of dyspepsia subgrouping.
Scand J Gastroenterol, 33 (1998), pp. 799-805
[55.]
M. Bustamante, M.J. Ferrando, F. Devesa, A. Borghol.
Predicción del diagnóstico endoscópico en el paciente con dispepsia: valor del síntoma predominante de presentación y de la presunción clínica inicial.
Gastroenterol Hepatol, 23 (2000), pp. 66-70
[56.]
M. Heikkinen, P. Pikkarainen, M. Eskelinen, R. Julkunen.
GPs’ ability to diagnose dyspepsia based only on physical examination and patient history.
Scand J Prim Health Care, 18 (2000), pp. 99-104
[57.]
Danish dyspepsia study group.
Value of the unaided clinical diagnosis in dyspeptic patients in primary care.
Am J Gastroenterol, 96 (2001), pp. 1.417-1.421
[58.]
R.C. Heading, E. Wager, P.J. Tooley.
Reliability of symptom assessment in dyspepsia.
Eur J Gastroenterol Hepatol, 9 (1997), pp. 779-781
[59.]
J.I. Westbrook, J.H. McIntosh, J.M. Duggan.
Accuracy of provisional diagnoses of dyspepsia in patients undergoing first endoscopy.
Gastrointest Endosc, 53 (2001), pp. 283-288
[60.]
M. Barenys, R. Rota, V. Moreno, R. Villafafila, I. García-Bayo, A. Abad, et al.
Validación prospectiva de un modelo clínico predictivo de dispepsia orgánica en el ámbito de la atención primaria y de las consultas de gastroenterología (Abstract).
astroenterol Hepatol, 26 (2003), pp. 103
[61.]
N.J. Talley, A.L. Weaver, D.L. Tesmer, A.R. Zinsmeister.
Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy.
Gastroenterology, 105 (1993), pp. 1.378-1.386
[62.]
N.J. Talley, A.R. Zinsmeister, C.D. Schleck, L.J. Melton 3rd.
Dyspepsia and dyspepsia subgroups: a population-based study.
Gastroenterology, 102 (1992), pp. 1.259-1.268
[63.]
L. Agreus, K. Svardsudd, O. Nyren, G. Tibblin.
Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time.
Gastroenterology, 109 (1995), pp. 671-680
[64.]
G. Holtmann, V. Stanghellini, N.J. Talley.
Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: clarifying the concepts.
Baillieres Clin Gastroenterol, 12 (1998), pp. 417-433
[65.]
P.T. Hession, J. Malagelada.
Review article: the initial management of uninvestigated dyspepsia in younger patients-the value of symptom-guided strategies should be reconsidered.
Aliment Pharmacol Ther, 14 (2000), pp. 379-388
[66.]
L.G. Madsen, P. Bytzer.
The value of alarm features in identifying organic causes of dyspepsia.
Can J Gastroenterol, 14 (2000), pp. 713-720
[67.]
Scottish Intercollegiate Guideline Network (SIGN). Dyspepsia. Edimburgh: SIGN, 2003 [en prensa]
[68.]
Alberta Clinical Practice Guideline Working Group. Guideline for Diagnosis and Treatment of Chronic Undiagnosed Dyspepsia in Adults. The Alberta Clinical Guideline Program. June, 2000
[69.]
Bristish Gastroenterology Society.
Dyspepsia Management Guidelines.
[70.]
R.P. Adang, A.W. Ambergen, J.L. Talmon, A. Hasman, J.F. Vismans, R.W. Stockbrugger.
The discriminative value of patient characteristics and dyspeptic symptoms for upper gastrointestinal endoscopic findings: a study on the clinical presentation of 1,147 patients.
Digestion, 57 (1996), pp. 118-134
[71.]
M.B. Wallace, V.L. Durkalski, J. Vaughan, Y.Y. Palesch, E.D. Libby, P.S. Jowell, et al.
Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study.
Gut, 49 (2001), pp. 29-34
[72.]
B. Williams, M. Luckas, J.H. Ellingham, A. Dain, A.C. Wicks.
Do young patients with dyspepsia need investigation?.
Lancet, 2 (1988), pp. 1.349-1.351
[73.]
J. Christie, N.A. Shepherd, B.W. Codling, R.M. Valori.
Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia.
Gut, 41 (1997), pp. 513-517
[74.]
D. Gillen, K.E. McColl.
Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55?.
Am J Gastroenterol, 94 (1999), pp. 75-79
[75.]
A. Heaney, J.S. Collins, T.C. Tham, P.R. Watson, J.R. McFarland, K.B. Bamford.
A prospective study of the management of the young Helicobacter pylori negative dyspeptic patientcan gastroscopies be saved in clinical practice?.
Eur J Gastroenterol Hepatol, 10 (1998), pp. 953-956
[76.]
C. Canga 3rd, N. Vakil.
Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy.
Am J Gastroenterol, 97 (2002), pp. 600-603
[77.]
American Gastroenterological Association medical position statement: evaluation of dyspepsia.
Gastroenterology, 114 (1998), pp. 579-581
[78.]
P. Malfertheiner, F. Megraud, C. O’Morain, A.P. Hungin, R. Jones, A. Axon, et al.
The European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection -the Maastricht 2-2000 Consensus Report.
Aliment Pharmacol Ther, 16 (2002), pp. 167-180
[79.]
J.J. Ofman, L. Rabeneck.
The effectiveness of endoscopy in the management of dyspepsia: a qualitative systematic review.
Am J Med, 106 (1999), pp. 335-346
[80.]
F. Cardin, M. Zorzi, A. Furlanetto, C. Guerra, F. Bandini, D. Polito, et al.
Are dyspepsia management guidelines coherent with primary care practice?.
Scand J Gastroenterol, 37 (2002), pp. 1.269-1.275
[81.]
M.T. Hallissey, W.H. Allum, A.J. Jewkes, D.J. Ellis, J.W. Fielding.
Early detection of gastric cancer.
BMJ, 301 (1990), pp. 513-515
[82.]
H.M. Sue-Ling, D. Johnston, I.G. Martin, M.F. Dixon, M.R. Lansdown, M.J. McMahon, et al.
Gastric cancer: a curable disease in Britain.
BMJ, 307 (1993), pp. 591-596
[83.]
M. Bustamante, F. Devesa, A. Borghol, M.J. Fernando.
Influencia de la edad en el diagnóstico endoscópico de los pacientes con dispepsia no complicada.
Rev Sdad Valenciana Patol Dig, 20 (2001), pp. 1-6
[84.]
N.P. Breslin, A.B. Thomson, R.J. Bailey, P.K. Blustein, J. Meddings, E. Lalor, et al.
Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia.
Gut, 46 (2000), pp. 93-97
[85.]
I.G. Martin, S. Young, H.M. Sue-Ling, D. Johnston.
Delays in the diagnosis of oesophagogastric cancer: a consecutive case series.
BMJ, 314 (1997), pp. 467-470
[86.]
S.M. Griffin, S.A. Raimes.
Proton pump inhibitors may mask early gastric cancer. Dyspeptic patients over 45 should undergo endoscopy before thesedrugs are started.
BMJ, 317 (1998), pp. 1.606-1.607
[87.]
Z. Suvakovic, M.G. Bramble, R. Jones, C. Wilson, N. Idle, J. Ryott.
Improving the detection rate of early gastric cancer requires more than open access gastroscopy: a five year study.
Gut, 41 (1997), pp. 308-313
[88.]
M.G. Bramble, Z. Suvakovic, A.P. Hungin.
Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy.
Gut, 46 (2000), pp. 464-467
[89.]
A.T. Lassen, F.M. Pedersen, P. Bytzer, O.B. Schaffalitzky de Muckadell.
Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial.
Lancet, 356 (2000), pp. 455-460
[90.]
R.J. Laheij, J.L. Severens, E.H. Van de Lisdonk, A.L. Verbeek, J.B. Jansen.
Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis.
Aliment Pharmacol Ther, 12 (1998), pp. 1.249-1.256
[91.]
J.M. Pajares.
Helicobacter pylori infection and gastric cancer in Spain.
Hepatogastroenterology, 48 (2001), pp. 1.556-1.559
[92.]
NHS Executive Referral Guidelines for Suspected Cancer.
[93.]
W.H. Allum, S.M. Griffin, A. Watson, D. Colin-Jones.
Guidelines for the management of oesophageal and gastric cancer.
Gut, (2002), pp. 1-23
[94.]
M.J. Buckley, C. Scanlon, P. McGurgan, C.A. O'Morain.
A validated dyspepsia symptom score.
Ital J Gastroenterol Hepatol, 29 (1997), pp. 495-500
[95.]
M.A. Mendall, R.P. Jazrawi, J.M. Marrero, N. Molineaux, J. Levi, J.D. Maxwell, et al.
Serology for Helicobacter pylori compared with symptom questionnaires in screening before direct access endoscopy.
Gut, 36 (1995), pp. 330-333
[96.]
P. Bytzer, J.M. Hansen, O.B. Schaffalitzky de Muckadell, A. Malchow-Moller.
Predicting endoscopic diagnosis in the dyspeptic patient. The value of predictive score models.
Scand J Gastroenterol, 32 (1997), pp. 118-125
[97.]
J.M. Coelho-Filho, J.W. Lima, G.B. Furtado, A. Castelo.
Development of a strategy to optimize the indications for the upper gastrointestinal endoscopy in patients with dyspepsia at the primary care level.
Rev Assoc Med Bras, 46 (2000), pp. 30-38
[98.]
C. Martín de Argila, D. Boixeda, R. Canton, N. Mir, L. de Rafael, J. Gisbert, et al.
Helicobacter pylori infection in a healthy population in Spain.
Eur J Gastroenterol Hepatol, 8 (1996), pp. 1.165-1.168
[99.]
G. Cilla, E. Pérez-Trallero, M. García-Bengoechea, J.M. Marimón, J.I. Arenas.
Helicobacter pylori infection: a seroepidemiological study in Gipuzkoa, Basque Country, Spain.
Eur J Epidemiol, 13 (1997), pp. 945-949
[100.]
A.M. Caballero, S. Kotoyannis, M. Valenzuela, F.J. Casado, J. Guilarte.
Epidemiología de la dispepsia en una población aleatoria mediterránea. Prevalencia de la infección por Helicobacter pylori.
Rev Esp Enferm Dig, 92 (2000), pp. 781-792
[101.]
M. García, J. Martí, I. León, D. Muñiz, J. Teruel, J.M. Baena, et al.
Prevalencia de la infección por Helicobacter pylori en atención primaria: estudio seroepidemiológico.
Aten Primaria, 29 (2002), pp. 553-557
[102.]
D.T. Smoot, M.F. Go, B. Cryer.
Peptic ulcer disease.
Prim Care, 28 (2001), pp. 487-503
[103.]
K. Bodger, M.J. Daly, R.V. Heatley.
Prescribing patterns for dyspepsia in primary care: a prospective study of selected general practitioners.
Aliment Pharmacol Ther, 10 (1996), pp. 889-895
[104.]
B.H. Folkersen, B. Larsen, P. Qvist.
General practitioners’ handling of patients with dyspepsia.
Ugeskr Laeger, 159 (1997), pp. 3.777-3.781
[105.]
G. Martínez-Sánchez, E. Saperas, J. Benavent, F. Mearin, J.L. Pinol, M. Barenys, et al.
Actitud de los médicos de atención primaria del área metropolitana de Barcelona frente al diagnóstico y tratamiento de la infección por Helicobacter pylori en enfermedades gastroduodenales.
Gastroenterol Hepatol, 21 (1998), pp. 473-478
[106.]
E. Gené, X. Calvet, R. Azagra, T. López, M.J. Cubells.
Manejo de la dispepsia, la enfermedad ulcerosa y la infección por Helicobacter pylori en atención primaria.
Aten Primaria, 29 (2002), pp. 486-494
[107.]
C.F. Weijnen, N.J. de Wit, M.E. Numans, A.O. Quartero, T.J. Verheij.
Dyspepsia management in primary care in the Netherlands: to what extent is Helicobacter pylori diagnosis and treatment incorporated? Results from a survey among general practitioners in the Netherlands.
Digestion, 64 (2001), pp. 40-45
[108.]
V. Meineche-Schmidt, G. Fly.
Helicobacter pylori test-and-treat strategy in dyspepsia patients in general practice Too many patients to treat?.
Gut, 43 (1999), pp. A355
[109.]
B. Delaney, P. Moayyedi, J. Deeks, M. Innes, S. Soo, P. Barton, et al.
The management of dyspepsia: a systematic review.
Health Technol Assess, 4 (2000),
[110.]
Delaney BC, Innes MA, Deeks J, Wilson S, Cooner MK, Moayyedi P et al. Initial management strategies for dyspepsia (Cochrane Review). En: The Cochrane Library, n.° 3, 2002. Oxford: Update Software
[111.]
B.M. Spiegel, N.B. Vakil, J.J. Ofman.
Dyspepsia management in primary care: a decision analysis of competing strategies.
Gastroenterology, 122 (2002), pp. 1.270-1.285
[112.]
National Institute for Clinical Excellence.
Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia. Londres: National Institute for Clinical. Excellence (NICE).
Technology Appraisal, (2000),
[113.]
A.O. Quartero, M.E. Numans, R.A. de Melker, A.W. Hoes, N.J. de Wit.
Dyspepsia in primary care: acid suppression as effective as prokinetic therapy. A randomized clinical trial.
Scand J Gastroenterol, 36 (2001), pp. 942-947
[114.]
S. Ghosh, M. Kinnear.
Dyspepsia in primary care to prescribe or to investigate?.
Br J Gen Pract, 51 (2001), pp. 612-614
[115.]
P.T. Hession, J. Malagelada.
Review article: the initial management of uninvestigated dyspepsia in younger patients -the value of symptom-guided strategies should be reconsidered.
Aliment Pharmacol Ther, 14 (2000), pp. 379-388
[116.]
N.T. Lewin van den Broek, M.E. Numans, E. Buskens, T.J. Verheij, N.J. de Wit, A.J. Smout.
A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome.
Br J Gen Pract, 51 (2001), pp. 619-624
[117.]
J.J. Ofman, L. Rabeneck.
The effectiveness of endoscopy in the management of dyspepsia: a qualitative systematic review.
Am J Med, 106 (1999), pp. 335-346
[118.]
L. Rabeneck, J. Souchek, K. Wristers, T. Menke, E. Ambriz, I. Huang, et al.
A double blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia.
Am J Gastroenterol, 97 (2002), pp. 3.045-3.051
[119.]
R. Brignoli, P. Watkins, F. Halter.
The Omega-Project -a comparison of two diagnostic strategies for risk -and cost-oriented management of dyspepsia.
Eur J Gastroenterol Hepatol, 9 (1997), pp. 337-343
[120.]
J.P. Gisbert, J.M. Pajares.
Helicobacter pylori “test-and-scope™ strategy for dyspeptic patients.
Helicobacter, 2 (2000), pp. 57-68
[121.]
G.M. Sobala, J.E. Crabtree, J.A. Pentith, B.J. Rathbone, T.M. Shallcross, J.I. Wyatt, et al.
Screening dyspepsia by serology to Helicobacter pylori.
Lancet, 338 (1991), pp. 94-96
[122.]
P. Patel, S. Khulusi, M.A. Mendall, R. Lloyd, R. Jazrawi, J.D. Maxwell, et al.
Prospective screening of dyspeptic patients by Helicobacter pylori serology.
Lancet, 346 (1995), pp. 1.315-1.318
[123.]
B.C. Delaney, S. Wilson, A. Roalfe, L. Roberts, V. Redman, A. Wearn, et al.
Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care.
BMJ, 322 (2001), pp. 898-901
[124.]
G. Rubin, V. Meineche-Schmidt, A. Roberts, N. de Wit.
The use of consensus to develop guidelines for the management of Helicobacter pylori infection in primary care.
Fam Pract, 17 (2000), pp. 21-26
[125.]
The European Helicobacter Study Group.
Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report.
Gut, 41 (1997), pp. 8-13
[126.]
R. Jones, C. Tait, G. Sladen, J. Weston-Baker.
A trial of a testand-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice.
Int J Clin Pract, 53 (1999), pp. 413-416
[127.]
A. Heaney, J.S. Collins, R.G. Watson, R.J. McFarland, K.B. Bamford, T.C. Tham.
A prospective randomised trial of a "test and treat" policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic.
Gut, 45 (1999), pp. 186-190
[128.]
K.E. McColl, L.S. Murray, D. Gillen, A. Walker, A. Wirz, J. Fletcher, et al.
Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia.
BMJ, 324 (2002), pp. 999-1.002
[129.]
J.P. Gisbert, J.M. Pajares.
Helicobacter pylori “test-and-treat™ strategy for dyspeptic patients.
Scand J Gastroenterol, 7 (1999), pp. 644-652
[130.]
A.J. Morris, C.F. Craig, C. Morran, H. Burns, K. Harden, A. Power, et al.
The influence of H. pylori status on symptoms and quality of life in patients receiving maintenance acid suppression therapy.
UEGW. Amsterdam, (2001),
[131.]
N. Chiba, S.J. Van Zanten, P. Sinclair, R.A. Ferguson, S. Escobedo, E. Grace.
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dys-pepsia empiric treatment -Helicobacter pylori positive (CADETHp) randomised controlled trial.
BMJ, 324 (2002), pp. 1.012-1.016
[132.]
Scottish Intercollegiate Guideline Network (SIGN). UPDATE H.
pylori: eradication therapy in dyspeptic disease.
[133.]
N.J. De Wit, A.O. Quartero, M.E. Numans.
Helicobacter pylori treatment instead of maintenance therapy for peptic ulcer disease: the effectiveness of case-finding in general practice.
Aliment Pharmacol Ther, 13 (1999), pp. 1.317-1.321
[134.]
Z. Khan, P. Nair, C. O'Shea, N. Spiers, R.J. Playford, A.C. Wicks.
Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study.
Scand J Gastroenterol, 37 (2002), pp. 144-147
[135.]
V. Meineche-Schmidt, G. Rubin, N.J. de Wit.
Helicobacter pylori infection: a comparative review of existing management guidelines.
Fam Pract, 17 (2000), pp. 2-5
[136.]
C.F. Weijnen, M.E. Numans, N.J. de Wit, A.J. Smout, K.G. Moons, T.J. Verheij, et al.
Testing for Helicobacter pylori in dyspeptic patients suspected of peptic ulcer disease in primary care: cross sectional study.
BMJ, 323 (2001), pp. 71-75
[137.]
H. Kolk, H.I. Maaroos, I. Kull, K. Labotkin, K. Loivukene, M. Mikelsaar.
Open access endoscopy in an epidemiological situation of high prevalence of Helicobacter pylori infection: applicability of the guidelines of the European Society for Primary Care Gastroenterology.
Fam Pract, 19 (2002), pp. 231-235
[138.]
R.F. Harvey, R.W. Spence, J.A. Lane, P. Nair, L.J. Murray, I.M. Harvey, et al.
Relationship between the birth cohort pattern of Helicobacter pylori infection and the epidemiology of duodenal ulcer.
QJM, 95 (2002), pp. 519-525
[139.]
Management of upper dyspepsia in general practice (funded by DACEHTA). Primary Research (project). Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). http://www.dihta.dk/projekter/230_uk.asp
[140.]
Gisbert JP, Khorrami, S Badia X, Pajares JM. La estrategia “test and treat™ (diagnosticar y tratar la infección por Helicobacter pylori) ante el paciente dispéptico en Atención Primaria. Club Español para el estudio del Helicobacter pylori. http://www.sepd.org/gaceta/hpclub.htm
[141.]
P. Bytzer, J.M. Hansen, O.B. Schaffalitzky de Muckadell.
Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia.
Lancet, 343 (1994), pp. 811-816
[142.]
B.C. Delaney, S. Wilson, A. Roalfe, L. Roberts, V. Redman, A. Wearn, et al.
Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care.
Lancet, 356 (2000), pp. 1.965-1.969
[143.]
J.K. Marshall, D. Armstrong, B.J. O'Brien.
Test and treat strategies for Helicobacter pylori in uninvestigated dyspepsia: a Canadian economic analysis.
Can J Gastroenterol, 14 (2000), pp. 379-388
[144.]
A.H. Briggs, M.J. Sculpher, R.P. Logan, J. Aldous, M.E. Ramsay, J.H. Baron.
Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.
BMJ, 312 (1996), pp. 1321-1325
[145.]
P. Moayyedi, J. Mason, A. Zilles, A.T.R. Axon, D.M. Chalmers, M.F. Drummond.
Screening and treating for H. pylori-Is it costeffective in clinical practice.
Digestion, 59 (1998), pp. 10
[146.]
A. Sonnenberg.
What to do about Helicobacter pylori? A decision analysis of its implication on public health.
Helicobacter, 7 (2002), pp. 60-66
[147.]
M.H. Ebell, L. Warbasse, C. Brenner.
Evaluation of the dyspeptic patient: a cost-utility study.
J Fam Pract, 44 (1997), pp. 545-555
[148.]
P. Moayyedi.
Helicobacter pylori test and treat strategy for young dyspeptic patients: new data.
Gut, 50 (2002), pp. 47-50
[149.]
A. García-Altés, R. Rota, M. Barenys, A. Abad.
“Test and treat™ and endoscopy are the most cost-effective strategies for the management of dyspepsia depending on the age of the patient. 18th Annual Meeting of the International Society of Technology Assessment in Health Care. ISTAHC.
Berlín, (2002),
[150.]
C.P. Dooley, A.W. Larson, N.H. Stace, I.G. Renner, J.E. Valenzuela, J. Eliasoph, et al.
Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study.
Ann Intern Med, 101 (1984), pp. 538-545
[151.]
J.M. Galloway, J. Gibson, J. Dalrymple.
Endoscopy in primary care: a survey of current practice.
Br J Gen Pract, 52 (2002), pp. 536-538
[152.]
P.C. Shaw, L.K. van Romunde, G. Griffioen, A.R. Janssens, J. Kreuning, G.A. Eilers.
Peptic ulcer and gastric carcinoma: diagnosis with biphasic radiography compared with fiberoptic endoscopy.
[153.]
P.C. Shaw, I.K.I. Romunde, G. Griffioen, A.R. Janssens, J. Kreuning, C.B.H.W. Lamers.
Detection of gastric erosions: comparison of biphasic radiography with fiberoptic endoscopy.
[154.]
RCR Working Party.
Making the best use of a Department of Clinical Radiology, 4.a ed.
[155.]
R.P. Logan, M.M. Walker.
ABC of the upper gastrointestinal tract: epidemiology and diagnosis of Helicobacter pylori infection.
BMJ, 323 (2001), pp. 920-922
[156.]
L.N. Meurer, D.J. Bower.
Management of Helicobacter pylori infection.
Am Fam Physician, 65 (2002), pp. 1.327-1.336
[157.]
A.P. Roberts, S.M. Childs, G. Rubin, N.J. de Wit.
Tests for Helicobacter pylori infection: a critical appraisal from primary care.
Fam Pract, 17 (2000), pp. 12-20
[158.]
C.T. Loy, L.M. Irwig, P.H. Katelaris, N.J. Talley.
Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis.
Am J Gastroenterol, 91 (1996), pp. 1.138-1.144
[159.]
M. Stevens, S. Livsey, R. Swann.
Evaluation of sixteen EIAs for the detection of antibodies to Helicobacter pylori.
pp. 1-46
[160.]
R.J. Laheij, H. Straatman, J.B. Jansen, A.L. Verbeek.
Evaluation of commercially available Helicobacter pylori serology kits: a review.
J Clin Microbiol, 36 (1998), pp. 2.803-2.809
[161.]
D. Vaira, N. Vakil.
Blood, urine, stool, breath, money, and Helicobacter pylori.
Gut, 48 (2001), pp. 287
[162.]
J.P. Gisbert, J.M. Pajares.
Serología “rápida™ para el diagnóstico de la infección por H. Pylori, ¿puede recomendarse su empleo sistemático en la práctica clínica?.
Med Clin (Barc), 118 (2002), pp. 196-197
[163.]
J.P. Gisbert, J.M. Pajares.
Diagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review.
Am J Gastroenterol, 96 (2001), pp. 2.829-2.838
[164.]
N. Vakil, D. Rhew, A. Soll, J.J. Ofman.
The cost-effectiveness of diagnostic testing strategies for H. pylori.
Am J Gastroenterol, 95 (2000), pp. 1.691-1.698
[165.]
V. Savarino, G. Bisso, M. Pivari, P. Zentilin, C. Bilardi, P. Dulbecco, et al.
Effect of gastric acid suppression on 13C-urea breath test: comparison of ranitidine with omeprazole.
Aliment Pharmacol Ther, 14 (2000), pp. 291-297
[166.]
V. Savarino, D. Tracci, P. Dulbecco, M.R. Mele, P. Zentilin, C. Mansi, et al.
Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori.
Am J Gastroenterol, 96 (2001), pp. 348-352
[167.]
S.J. Connor, F. Seow, M.C. Ngu, P.H. Katelaris.
The effect of dosing with omeprazole on the accuracy of the 13C-urea breath test in Helicobacter pylori-infected subjects.
Aliment Pharmacol Ther, 13 (1999), pp. 1.287-1.293
[168.]
S.J. Connor, M.C. Ngu, P.H. Katelaris.
The impact of short-term ranitidine use on the precision of the 13C-urea breath test in subjects infected with Helicobacter pylori.
Eur J Gastroenterol Hepatol, 11 (1999), pp. 1.135-1.138
[169.]
L. Laine, R. Estrada, M. Trujillo, K. Knigge, M.B. Fennerty.
Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.
Ann Intern Med, 129 (1998), pp. 547-550
[170.]
J.P. Gisbert, M.M. Cabrera, J.M. Pajares.
Detección del antígeno de Helicobacter pylori en heces para el diagnóstico inicial de la infección y para la confirmación de su erradicación tras el tratamiento.
Med Clin (Barc), 118 (2002), pp. 401-404
[171.]
M.J. Schmulson, E.A. Mayer.
Gastrointestinal sensory abnormalities in functional dyspepsia.
Baillieres Clin Gastroenterol, 12 (1998), pp. 545-556
[172.]
J.R. Malagelada.
Functional dyspepsia. Insights on mechanisms and management strategies.
Gastroenterol Clin North Am, 25 (1996), pp. 103-112
[173.]
Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia (Cochrane Review). En: The Cochrane Library, n.° 3, 2002. Oxford: Update Software
[174.]
F.S. Finney, N. Kinnersley, M. Hughes, C.G. O’Bryan-Tear, J. Lothian.
Meta-analysis of antisecretory and gastrokineticcompounds in functional dyspepsia.
J Clin Gastroenterol, 26 (1998), pp. 312-320
[175.]
H.D. Allescher, A. Bockenhoff, G. Knapp, M. Wienbeck, J. Hartung.
Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies.
Scand J Gastroenterol, 36 (2001), pp. 934-941
[176.]
H.A. Redstone, N. Barrowman, S.J. Veldhuyzen Van Zanten.
H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials.
Aliment Pharmacol Ther, 15 (2001), pp. 1.291-1.299
[177.]
J.Y. Shiau, K. Vijay, B. Shula, C. Dubé.
The efficacy of proton pump inhibitors in adults with functional dyspepsia.
[178.]
N.J. Talley, K. Lauritsen.
The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies.
Gut, 50 (2002), pp. 36-41
[179.]
A.L. Blum, R. Arnold, M. Stolte, M. Fischer, H.R. Koelz.
The Frosch Study Group. Short course acid suppesive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status.
Gut, 47 (2000), pp. 473-480
[180.]
V.K. Shukla, N. Otten, C. Dubé, D. Moher.
Use of cisapride in patients with non-ulcer dyspepsia: a meta-analysis of randomized trials.
[181.]
J.O. Sander, S.J.O. Veldhuyzen van Zanten, M.J. Jones, M. Verlinden, N.J. Talley.
Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis.
Am J Gastroenterol, 96 (2001), pp. 689-696
[182.]
Cisaprida for non ulcer dyspepsia.
Bandolier, (2000), pp. 76-173
[183.]
V. Arienti, G.R. Corazza, M. Sorge, L. Boriani, F. Ugenti, F. Biagi, et al.
The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia.
Aliment Pharmacol Ther, 8 (1994), pp. 631-638
[184.]
G.R. Corazza, F. Biagi, O. Albano, G.B. Porro, R. Cheli, G. Mazzacca, et al.
Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial.
Ital J Gastroenterol, 28 (1996), pp. 317-323
[185.]
C.W. Song, H.J. Chun, C.D. Kim, H.S. Ryu, J.G. Choe, J.H. Hyun.
Effects of levosulpiride in patients with functional dyspepsia accompanied by delayed gastric emptying.
Korean J Intern Med, 13 (1998), pp. 15-21
[186.]
C. Mansi, P. Borro, M. Giacomini, R. Biagini, M.R. Mele, N. Pandolfo, et al.
Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis.
Aliment Pharmacol Ther, 14 (2000), pp. 561-569
[187.]
B.I. Hallerback, G. Bommelaer, E. Bredberg, M. Campbell, M. Hellblom, K. Lauritsen, et al.
Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study.
Aliment Pharmacol Ther, 5 (2002), pp. 959-967
[188.]
Soo S, Moayyedi P, Deeks J, Delaney B, Lewis M, Forman D. Psychological interventions for non-ulcer dyspepsia (Cochrane Review). En: The Cochrane Library, n.° 3, 2002. Oxford: Update Software
[189.]
J.L. Jackson, P.G. O'Malley, G. Tomkins, E. Baldin, J. Santoro, K. Kroenke.
Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis.
Am J Med, 108 (2000), pp. 65-72
[190.]
E.L. Calvert, L.A. Houghton, P. Cooper, J. Morris, P.J. Whorwell.
Long-term improvement in functional dispepsia using hypnoterapy.
Gastroenterology, 123 (2002), pp. 1.778-1.785
[191.]
R.L. Jaakkimainen, E. Boyle, F. Tudiver.
Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms?.
A meta-analysis BMJ, 319 (1999), pp. 1.040-1.044
[192.]
L. Laine, P. Schoenfeld, M.B. Fennerty.
Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials.
Ann Intern Med, 134 (2001), pp. 361-369
[193.]
J.P. Gisbert, X. Calvet, R. Gabriel, J.M. Pajares.
Infección por Helicobacter pylori y dispepsia funcional. Metaanálisis de la eficacia del tratamiento erradicador.
Med Clin (Barc), 118 (2002), pp. 405-409
[194.]
Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia (Cochrane Review). En: The Cochrane Library, n.° 3, 2002. Oxford: Update Software
[196.]
P.I. Hsu, K.H. Lai, H.H. Tseng, G.H. Lo, C.C. Lo, C.K. Lin, et al.
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Aliment Pharmacol Ther, 15 (2001), pp. 195-201
[197.]
H.R. Koelz, R. Arnold, M. Stolte, M. Fischer, A.L. Blum.
The Frosch Study Group. Treatment of Helicobacter pylori in functional dispepsia resistant to conventional management: a double blind randomised trial with a six month follow up.
Gut, 52 (2003), pp. 40-46
[198.]
R.A. Moore.
Helicobacter pylori and peptic ulcer: a systematic review of effectiveness and an overview of the economic benefits of implementing what is known to be effective.
[199.]
J.G. Penston.
Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease.
Aliment Pharmacol Ther, 10 (1996), pp. 469-486
[200.]
L. Laine, R.J. Hopkins, L.S. Girardi.
Has the impact of Heli-cobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials.
Am J Gastroenterol, 93 (1998), pp. 1.409-1.415
[201.]
Forman D, Bazzoli F, Bennett C, Broutet N, Calvet-Calvo X, Chiba N et al. Therapies for the eradication of Helicobacter pylori (Protocol for a Cochrane Review). En: The Cochrane Library, n.° 4, 2002. Oxford: Update Software
[202.]
B. Delaney, P. Moayyedi, D. Forman.
Helicobacter pylori infection.
Clin Evid, 7 (2002), pp. 414-428
[203.]
C.W. Howden, R.H. Hunt.
Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology.
Am J Gastroenterol, 93 (1998), pp. 2.330-2.338
[204.]
J.P. Gisbert, X. Calvet, F. Gomollón, R. Sainz.
Conferencia de consenso. Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la Conferencia Española de Consenso.
Med Clin (Barc), 114 (2000), pp. 185-195
[205.]
A. Leodolter, M. Kulig, H. Brasch, W. Meyer-Sabellek, S.N. Willich, P. Malfertheiner.
A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pyloriassociated gastric or duodenal ulcer.
Aliment Pharmacol Ther, 15 (2001), pp. 1.949-1.958
[206.]
J.P. Gisbert, D. Boixeda, C.M. de Argila, F. Bermejo, C. Redondo, L. de Rafael.
Erosive duodenitis: prevalence of Helicobacter pylori infection and response to eradication therapy with omeprazole plus two antibiotics.
Eur J Gastroenterol Hepatol, 9 (1997), pp. 957-962
[207.]
A. Shiotani, S. Nishioka, M. Iguchi, K. Yanaoka, K. Okada, H. Tamai, et al.
Duodenal erosions after eradication of Helicobacter pylori infection.
Gastrointest Endosc, 54 (2001), pp. 448-453
[208.]
L. Laine, H. Cohen, R. Sloane, M. Marin-Sorensen, W.M. Weinstein.
Interobserver agreement and predictive value of endoscopic findings for H. pylori and gastritis in normal volunteers.
Gastrointest Endosc, 42 (1995), pp. 420-423
[209.]
A. Vincze, O. Karadi, B. Hunyady, F. Pakodi, G. Suto, G. Mozsik.
One year follow-up of patients after successful Helicobacter pylori eradication therapy.
J Physiol Paris, 95 (2001), pp. 457-460
[210.]
F.S. Lehmann, E.L. Renner, B. Meyer-Wyss, C.H. Wilder-Smith, L. Mazzucchelli, C. Ruchti, et al.
Helicobacter pylori and gastric erosions. Results of a prevalence study in asymptomatic volunteers.
Digestion, 62 (2000), pp. 82-86
[211.]
V. Kate, N. Ananthakrishnan, S. Badrinath, S.K. Amarnath, M. Balamurugan, C. Ratnakar.
Helicobacter pylori infection and erosive gastritis.
J Assoc Physicians India, 46 (1998), pp. 436-437
[212.]
A.S. Taha, R.D. Sturrock, R.I. Russell.
Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori.
Gut, 36 (1995), pp. 334-336
[213.]
B. Annibale, M. Marignani, B. Monarca, G. Antonelli, A. Marcheggiano, G. Martino, et al.
Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis.
Ann Intern Med, 131 (1999), pp. 668-672
[214.]
S.J. Veldhuyzen van Zanten, P.M. Sherman.
Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview.
CMAJ, 150 (1994), pp. 177-185
[215.]
K.E. McColl.
The role of Helicobacter pylori eradication in the management of acute bleeding peptic ulcer.
Eur J Gastroenterol Hepatol, 7 (1995), pp. 753-755
[216.]
V.K. Sharma, A.V. Sahai, F.A. Corder, C.W. Howden.
Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage.
Aliment Pharmacol Ther, 15 (2001), pp. 1.939-1.947
[217.]
S.M. Buring, L.H. Winner, R.C. Hatton, P.L. Doering.
Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis.
Pharmacotherapy, 19 (1999), pp. 324-332
[218.]
J.G. Penston, K.E. McColl.
Eradication of Helicobacter pylori: an objective assessment of current therapies.
Br J Clin Pharmacol, 43 (1997), pp. 223-243
[219.]
R.J. Laheij, L.G. Rossum, J.B. Jansen, H. Straatman, A.L. Verbeek.
Evaluation of treatment regimens to cure Helicobacter pylori infection -a meta-analysis.
Aliment Pharmacol Ther, 13 (1999), pp. 857-864
[220.]
T. Lind, S. Veldhuyzen van Zanten, P. Unge, R. Spiller, E. Bayerdorffer, C. O'Morain, et al.
Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.
Helicobacter, 1 (1996), pp. 138-144
[221.]
H. Miwa, R. Ohkura, T. Murai, K. Sato, A. Nagahara, S. Hirai, et al.
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
Aliment Pharmacol Ther, 13 (1999), pp. 741-746
[222.]
B.C. Wong, W.M. Wong, Y.K. Yee, W.K. Hung, A.W. Yip, M.L. Szeto, et al.
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
Aliment Pharmacol Ther, 15 (2001), pp. 1.959-1.965
[223.]
K. Murakami, R. Sato, T. Okimoto, M. Nasu, T. Fujioka, M. Kodama, et al.
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Aliment Pharmacol Ther, 16 (2002), pp. 1.933-1.938
[224.]
S. Veldhuyzen Van Zanten, K. Lauritsen, J.C. Delchier, J. Labenz, C.M. De Argila, T. Lind, et al.
One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease.
Aliment Pharmacol Ther, 14 (2000), pp. 1.605-1.611
[225.]
Z. Tulassay, A. Kryszewski, P. Dite, D. Kleczkowski, J. Rudzinski, Z. Bartuzi, et al.
One week of treatment with esomeprazolebased triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease.
Eur J Gastroenterol Hepatol, 13 (2001), pp. 1.457-1.465
[226.]
L. Laine.
Esomeprazole in the treatment of Helicobacter pylori.
Aliment Pharmacol Ther, 16 (2002), pp. 115-118
[227.]
C.H. Schmid, G. Whiting, D. Cory, S.D. Ross, T.C. Chalmers.
Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: a meta-regression analysis of randomized, controlled trials.
Am J Ther, 6 (1999), pp. 25-36
[228.]
L.A. Fischbach, K.J. Goodman, M. Feldman, C. Aragaki.
Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis.
Int J Epidemiol, 31 (2002), pp. 128-139
[229.]
Jovell AJ, Aymerich M, García-Altés A, Serra-Prat M. Guia de pràctica clínica del tractament erradicador de la infecció per Helicobacter pylori associada a l'úlcera duodenal en l’atenció primària. Barcelona: Agència d'Avaluació de Tecnologia Mèdica. Servei Català de la Salut. Departament de Sanitat i Seguretat Social. Generalitat de Catalunya: setembre de 1998
[230.]
J. Huang, R.H. Hunt.
The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.
Aliment Pharmacol Ther, 13 (1999), pp. 719-729
[231.]
J.P. Gisbert, J.M. Pajares.
Resistencia de Helicobacter pylori al metronidazol y a la claritromicina en España. Una revisión sistemática.
Med Clin (Barc), 116 (2001), pp. 111-116
[232.]
E. Cuchí, M. Forné, S. Quintana, J. Lite, J. Garau.
Evolución de la sensibilidad de 235 cepas de Helicobacter pylori entre 1995 y 1998 e impacto del tratamiento antibiótico.
Enferm Infecc Microbiol Clin, 20 (2002), pp. 157-160
[233.]
J.P. Gisbert, X. Calvet, L. Bujanda.
Usefulness of 14-day rifabutin, amoxicillin and omeprazole triple therapy as a rescue therapy after multiple treatment failures.
Helicobacter, (2003),
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.